News
Ocugen Q2 Earnings Call Highlights
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an
OmniAb Q2 Earnings Call Highlights
OmniAb (NASDAQ:OABI) reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and
Nova Q2 Earnings Call Highlights
Nova (NASDAQ:NVMI) reported record second-quarter revenue of $255 million, up 8% sequentially and 16% from a year earlier, as demand
Novavax Q2 Earnings Call Highlights
Novavax (NASDAQ:NVAX) reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in
Natera Q2 Earnings Call Highlights
Natera (NASDAQ:NTRA) reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase
Microvision Q2 Earnings Call Highlights
Key Points
- Interested in Microvision, Inc.? Here are five stocks we like better.
- Revenue and margins improved: MicroVision reported Q2 2026 revenue of $1.5 million, up $1.3 million year over
nLight Q2 Earnings Call Highlights
Key Points
- Interested in nLight? Here are five stocks we like better.
- nLight reported record second-quarter results: Revenue rose 34% year over year to $82.6 million, product revenue increased
iRhythm Technologies Q2 Earnings Call Highlights
Key Points
- Interested in iRhythm Technologies? Here are five stocks we like better.
- Strong Q2 performance: Revenue rose 20.1% year over year to $224.2 million, while adjusted EBITDA reached
INmune Bio Q2 Earnings Call Highlights
Key Points
- Interested in INmune Bio, Inc.? Here are five stocks we like better.
- Regulatory and manufacturing progress: INmune Bio plans to seek conditional U.K. approval for Ebstrocel in late
Inogen Q2 Earnings Call Highlights
Key Points
- Interested in Inogen, Inc? Here are five stocks we like better.
- Second-quarter revenue rose 3% to $95.1 million, with international sales up 15% and new products helping offset a 2%
Bayer Aktie: Glyphosat-Anhörung frühestens am 14. September
Bayer und die Klägerseite im US-Glyphosat-Streit haben gemeinsam beantragt, die Anhörung zur endgültigen Genehmigung…
Der Beitrag Bayer Aktie: Glyphosat-Anhörung frühestens am 14. September erschien
Halozyme Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Halozyme Therapeutics, Inc.? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 48% year over year to $481 million, while royalty revenue increased
Cytokinetics Q2 Earnings Call Highlights
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYQORZO’s U.S. launch is gaining traction: The drug reached 1,500 dispensed patients and more than 700
CVRx Q2 Earnings Call Highlights
Key Points
- Interested in CVRx, Inc.? Here are five stocks we like better.
- CVRx lowered its 2026 outlook due to sales-force turnover, slower territory-manager productivity ramps and
CytomX Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in CytomX Therapeutics, Inc.? Here are five stocks we like better.
- Varseta-M remains CytomX’s primary focus: The Phase I monotherapy study has enrolled 113 patients, with
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Corvus Pharmaceuticals, Inc.? Here are five stocks we like better.
- Corvus reported a wider Q2 loss as research and development spending rose to $16 million for
BioMarin Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better.
- BioMarin’s second-quarter revenue nearly reached $1 billion, rising 20% year over year. The company
Ardelyx Q2 Earnings Call Highlights
Key Points
- Interested in Ardelyx, Inc.? Here are five stocks we like better.
- Second-quarter product revenue reached a record $118 million, up 31% year over year, but Ardelyx lowered its 2026
Arcturus Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Arcturus Therapeutics Holdings Inc.? Here are five stocks we like better.
- ARCT-032 cystic fibrosis study remains on track: Phase II enrollment is active in the U.S
Ligand Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Ligand Pharmaceuticals Incorporated? Here are five stocks we like better.
- Q2 results strengthened: Revenue rose 34% year over year to $64 million, royalty revenue
Kulicke and Soffa Industries Q3 Earnings Call Highlights
Key Points
- Interested in Kulicke and Soffa Industries, Inc.? Here are five stocks we like better.
- Strong fiscal third-quarter performance: Revenue rose 36.2% sequentially and 123% year over
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Ironwood Pharmaceuticals, Inc.? Here are five stocks we like better.
- LINZESS sales strengthened: U.S. second-quarter sales rose 14% to $282.3 million, prompting
Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting
Key Points
- Interested in Orion Energy Systems, Inc.? Here are five stocks we like better.
- Fiscal 2026 results improved: Revenue rose to $86.3 million from $79.7 million, gross margin increased
Insmed Q2 Earnings Call Highlights
Key Points
- Interested in Insmed, Inc.? Here are five stocks we like better.
- BRINSUPRI sales accelerated: Second-quarter revenue reached $309.2 million, up 49% sequentially, prompting Insmed to